2-fluorofucose

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
2-fluorofucose
Accession Number
DB15302
Description

2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 166.148
Monoisotopic: 166.064136997
Chemical Formula
C6H11FO4
Synonyms
  • SGN-2FF

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
W39886N0ZG
CAS number
70763-62-1
InChI Key
SQTFKIKSQNCWGJ-KCDKBNATSA-N
InChI
InChI=1S/C6H11FO4/c1-3(9)5(10)6(11)4(7)2-8/h2-6,9-11H,1H3/t3-,4+,5+,6-/m0/s1
IUPAC Name
(2S,3R,4R,5S)-2-fluoro-3,4,5-trihydroxyhexanal
SMILES
C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O

References

General References
Not Available
ChemSpider
111855
ZINC
ZINC000006030222

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Breast Cancer / Cancer, Bladder / Carcinoma, Squamous Cell of Head and Neck / Colorectal Cancers / Gastric Adenocarcinoma / Head and Neck Carcinoma / Neoplasms, Breast / Neoplasms, Colorectal / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma / Urinary Bladder Neoplasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility115.0 mg/mLALOGPS
logP-0.97ALOGPS
logP-1.6ChemAxon
logS-0.16ALOGPS
pKa (Strongest Acidic)12.31ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area77.76 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity34.11 m3·mol-1ChemAxon
Polarizability14.49 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 09:10 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates